Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Burhan Ferhanoglu, Tae Min Kim, Amado Karduss, David Brittain, Gayane Tumyan, Mubarak Al-mansour, Marta Zerga, Yuqin Song, Silvia Rivas-Vera, Yok Lam Kwong, Soon Thye Lim, Su-Peng Yeh, Arif Abdillah, Zhongwen Huang, Mehul Dalal, Hui Wan & Mark Hertzberg. (2022) Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study. Leukemia & Lymphoma 63:14, pages 3317-3330.
Read now
Read now
Wouter J. Plattel, Aurore Bergamasco, Fabrizio Trinchese, François Gavini, Nawal Bent-Ennakhil, Athanasios Zomas, Genaro Castillon, Teigna Arredondo-Bisono, Tiffany Cristarella, Yola Moride & Bastian von Tresckow. (2021) Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leukemia & Lymphoma 62:14, pages 3320-3332.
Read now
Read now
Alexander Fosså, Knut Smeland, Unn-Merete Fagerli, Renate B. Galleberg, Hanne S. Bersvendsen & Harald Holte. (2020) Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016. Acta Oncologica 59:1, pages 101-105.
Read now
Read now
Ioannis Petrakis, Christos Kontogiorgis, Evangelia Nena, Kostas Athanasakis, Vasiliki Gougoula, Ioannis Kotsianidis & Theodoros C. Constantinidis. (2019) Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma. Expert Review of Hematology 12:12, pages 1063-1075.
Read now
Read now
Articles from other publishers (11)
Vivek S. Radhakrishnan, Jemma Longley & Peter W.M. Johnson. (2024) Antibody based therapies in Hodgkin lymphoma. Cancer Treatment Reviews 122, pages 102647.
Crossref
Crossref
Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu & Mingzhi Zhang. (2023) Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study. Cancer Medicine.
Crossref
Crossref
Clementine Nordon, Benoit Sanchez, Mei Zhang, Xiaowei Wang, Phillip Hunt, Mark Belger & Helene Karcher. (2023) Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness. Contemporary Clinical Trials Communications 33, pages 101142.
Crossref
Crossref
Alnecia R Nisbett, Xiaoqin Yang, Patrick Squires, Santosh Gautam, Kaushal Desai, Monika Raut & Akash Nahar. (2022) Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma. Future Oncology 18:32, pages 3623-3636.
Crossref
Crossref
Vivek S. Radhakrishnan, Rajat Bajaj, Vasundhara Raina, Jeevan Kumar, Saurabh J. Bhave, Reghu K. Sukumaran Nair, Arijit Nag, Indu Arun, Lateef Zameer, Debdeep Dey, Neeraj Arora, Mayur Parihar, Jayanta Das, Rimpa B. Achari, Deepak K. Mishra, Mammen Chandy & Reena Nair. (2022) Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review. Frontiers in Oncology 11.
Crossref
Crossref
Roser Velasco, Eva Domingo-Domenech & Anna Sureda. (2021) Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers 13:23, pages 6125.
Crossref
Crossref
Murat Özbalak, Ayşe Salihoğlu, Teoman Soysal, İhsan Karadoğan, Semra Paydaş, Evren Özdemir, Birol Yıldız, Nuri Karadurmuş, Leylagül Kaynar, Münci Yagci, Vildan Özkocaman, Pervin Topçuoğlu, Muhit Özcan, Elif Birtaş, Hakan Göker & Burhan Ferhanoglu. (2019) Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Annals of Hematology 99:2, pages 301-307.
Crossref
Crossref
Helen Ma, Bin Cheng, Francesca Montanari, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Owen A. O’ Connor & Ahmed Sawas. (2020) Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances in Hematology 11, pages 204062072094734.
Crossref
Crossref
Theodoros P. Vassilakopoulos, Chrysovalantou Chatzidimitriou, John V. Asimakopoulos, Maria Arapaki, Evangelos Tzoras, Maria K. Angelopoulou & Kostas Konstantopoulos. (2019) Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers 11:8, pages 1071.
Crossref
Crossref
Theodoros P Vassilakopoulos & Boris Böll. (2019) Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care. European Oncology & Haematology 15:1, pages 53.
Crossref
Crossref
Mahmoud A. Elshenawy, M. Shahzad Rauf, Tusneem A.M. Elhassan, Irfan Maghfoor & Saad Akhtar. (2018) Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Annals of Hematology 97:7, pages 1229-1240.
Crossref
Crossref